[go: up one dir, main page]

EE200100377A - Use of Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones as Medicines - Google Patents

Use of Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones as Medicines

Info

Publication number
EE200100377A
EE200100377A EEP200100377A EEP200100377A EE200100377A EE 200100377 A EE200100377 A EE 200100377A EE P200100377 A EEP200100377 A EE P200100377A EE P200100377 A EEP200100377 A EE P200100377A EE 200100377 A EE200100377 A EE 200100377A
Authority
EE
Estonia
Prior art keywords
pyrazinones
pyrido
imidazo
medicines
Prior art date
Application number
EEP200100377A
Other languages
Estonian (et)
Inventor
H�Fgen Norbert
Szelenyi Stefan
Degenhard Marx
Egerland Ute
Original Assignee
Arzneimittelwerk Dresden Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/en
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/en
Application filed by Arzneimittelwerk Dresden Gmbh filed Critical Arzneimittelwerk Dresden Gmbh
Publication of EE200100377A publication Critical patent/EE200100377A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100377A 1999-01-20 2000-01-14 Use of Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones as Medicines EE200100377A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (en) 1999-01-20 1999-01-20 New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction
DE1999161302 DE19961302A1 (en) 1999-12-18 1999-12-18 Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders
PCT/EP2000/000260 WO2000043392A2 (en) 1999-01-20 2000-01-14 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments

Publications (1)

Publication Number Publication Date
EE200100377A true EE200100377A (en) 2002-10-15

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100377A EE200100377A (en) 1999-01-20 2000-01-14 Use of Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones as Medicines

Country Status (23)

Country Link
EP (1) EP1144410A2 (en)
JP (1) JP2002535330A (en)
KR (1) KR20010101603A (en)
CN (1) CN1344268A (en)
AR (1) AR022318A1 (en)
AU (1) AU2291200A (en)
BG (1) BG105714A (en)
BR (1) BR0007613A (en)
CA (1) CA2296224A1 (en)
CO (1) CO5190700A1 (en)
CZ (1) CZ20012627A3 (en)
EA (1) EA200100792A1 (en)
EE (1) EE200100377A (en)
HU (1) HUP0105132A3 (en)
ID (1) ID29790A (en)
IL (1) IL144156A0 (en)
IS (1) IS5987A (en)
LT (1) LT2001078A (en)
LV (1) LV12793B (en)
NO (1) NO20013334L (en)
SK (1) SK10322001A3 (en)
TR (1) TR200102121T2 (en)
WO (1) WO2000043392A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU2002361417A1 (en) * 2001-12-17 2003-06-30 Altana Pharma Ag Use of selective PDE5 inhibitors for treating partial and global respiratory failure
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (en) * 2002-02-12 2006-05-05 Oreal NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
WO2008072779A1 (en) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
JP2011505366A (en) 2007-11-30 2011-02-24 ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
AU2012323085B2 (en) 2011-10-10 2017-03-09 H. Lundbeck A/S PDE9i with imidazo pyrazinone backbone
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (en) * 2012-01-31 2016-01-13 株式会社東洋新薬 Phosphodiesterase 3 inhibitor
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
JP2021526134A (en) 2018-05-25 2021-09-30 イマラ インク． 6-[(3S, 4S) -4-methyl-l- (pyrimidine-2-ylmethyl) pyrrolidine-3-yl] -3-tetrahydropyran-4-yl-7H-imidazole [l, 5-A] pyrazine- 8-one monohydrate and crystalline form
KR20250108770A (en) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. Pde9 inhibitors for treating sickle cell disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (en) * 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation

Also Published As

Publication number Publication date
CO5190700A1 (en) 2002-08-29
TR200102121T2 (en) 2002-01-21
EA200100792A1 (en) 2002-10-31
HUP0105132A2 (en) 2002-05-29
NO20013334D0 (en) 2001-07-05
LV12793A (en) 2002-02-20
HUP0105132A3 (en) 2002-12-28
EP1144410A2 (en) 2001-10-17
CZ20012627A3 (en) 2002-01-16
WO2000043392A2 (en) 2000-07-27
JP2002535330A (en) 2002-10-22
CA2296224A1 (en) 2000-07-20
LV12793B (en) 2002-05-20
AR022318A1 (en) 2002-09-04
IS5987A (en) 2001-06-29
ID29790A (en) 2001-10-11
BR0007613A (en) 2001-10-30
IL144156A0 (en) 2002-05-23
BG105714A (en) 2002-02-28
NO20013334L (en) 2001-07-05
AU2291200A (en) 2000-08-07
SK10322001A3 (en) 2002-07-02
KR20010101603A (en) 2001-11-14
WO2000043392A3 (en) 2000-09-28
CN1344268A (en) 2002-04-10
LT2001078A (en) 2002-08-26

Similar Documents

Publication Publication Date Title
DK1214318T3 (en) Imidazo [1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives
EE200100377A (en) Use of Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones as Medicines
ID29514A (en) 2-ARIL-3- (HETEROARIL) -IMIDAZO [1,2-a] SUBSTITUTED PYRIMIDINE, AND RELATED PHARMACEUTICAL METHODS AND COMPOSITIONS
IL191960A (en) Imidazo[1,5-a]pyridine derivatives and pharmaceutical compositions comprising the same
EP1212327B8 (en) Pyrazolopyrimidines as therapeutic agents
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
AU7922900A (en) Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
NO20020391D0 (en) 8-Phenyl-6,9-dihydro- [1,2,4] triazolo [3,4-i] purin-5-one derivatives
NO20000394L (en) 1,2,4-triazolo [4,3-B] pyrido [3,2-D] pyridazine derivatives as well as pharmaceutical compositions containing such
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
DE60103909D1 (en) 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO [1,2-A] PYRIMIDIN-4-ON- AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO [1,2-A] PYRIMIDIN-5 1HON DERIVATIVES
FR2832711B1 (en) TRIAZOLO [4,3-A] PYRIDO [2,3-D] PYRIMIDIN-5-ONES DERIVATIVES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PREPARATION AND USE
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
NO20013645L (en) Use of Pyridazino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disease-Related Dysfunction of the Peripheral Benzodiazepine Receptors
PL366858A1 (en) Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
NO20013384D0 (en) Imidazo [4,5-c] pyridine-4-one derivatives
EE200400078A (en) Inhalation compositions containing tricyclic 5,6-dihydro-9H-pyrazolo [3,4-c] -1,2,4-triazolo [4,3-alpha] pyridines
SI1560830T1 (en) Derivatives of (6, 7-dihydro-5h-imidazo(1,2 - a)imidazole -3 -sulfonylamino)-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
MXPA03008894A (en) Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments.
ITMI991740A0 (en) DERIVATIVES OF 1H-PYRIDO 3,4-B INDOL-1-ONE
NO20014729L (en) Derivatives of pyrimido [6,1-a] isoquinolin-4-one
NO20016271D0 (en) Process for the preparation of substituted [1,4] diazepino [6,7,1-hi] indol-4-ones
AU2002302503A1 (en) Use of substituted imidazo[1,2-A]-pyridine-3-yl-amide and imidazo[1,2-A]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases